Catalog4 refs
Octreotide
OtherResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Overview
A synthetic eight-amino-acid mimic of the natural hormone somatostatin, the body's main 'off switch' for hormone secretion. It binds somatostatin receptors SSTR2 and SSTR5 with high affinity, clamping down on adenylate cyclase and calcium channels inside hormone-producing cells, which throttles the release of growth hormone, glucagon, insulin, gastrin, and several gut hormones. In acromegaly it drops growth hormone output from the pituitary tumor, lowering IGF-1. It also slows gut motility and reduces splanchnic blood flow, calming carcinoid-related diarrhea. FDA-approved for multiple indications including acromegaly and carcinoid syndrome.
Primary Uses
Acromegaly
Carcinoid syndrome
Neuroendocrine tumors
Reducing excess growth hormone secretion
Controlling carcinoid-related diarrhea and flushing
Slowing tumor progression in neuroendocrine tumors
Protocol Reference
Dose
100-500 mcg SC 2-3x daily or LAR monthly; range 50-1500 mcg daily (SC); 20-40 mg IM monthly (LAR)
Frequency
2-3x daily (SC) or monthly (LAR)
Route
Subcutaneous · Intramuscular depot
Evidence
FDA Approved
Research References· 1
Research Models
Human
Also in Other